Diagnosing HF requires objective estimation of cardiac function (i.e. Echo) since determining the aetiology and stage of HF leads to different management choices such as initiation of angiotensin-converting enzyme (ACE) inhibitors [10], ß-blockers [11] and aldosterone antagonists in most patients with LVSD [15], cardiac resynchronization therapy for those with LVSD and broad QRS complex [1], or surgery where significant valve disease exists. This evidence concerns the gene ACE and hydrops fetalis.